Recent Updates
Recently added Catalysts
ENTA Positive Sentiment

EPS-3903, a Potent, Oral STAT6 Inhibitor, Exhibits Preferential Lung and Alveolar Macrophage Distribution with Low Drug–Drug Interaction Potential for the Treatment of Asthma

Tuesday, May 19, 2026 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: EPS-3903 is a novel oral STAT6 inhibitor that demonstrates a preferential distribution in lung and alveolar macrophages, making it a promising candidate for asthma treatment. Its low drug-drug interaction potential further enhances its therapeutic profile, positioning it as a significant advancement in asthma management. The findings suggest a targeted approach to treating respiratory conditions.
Price reaction · baseline $13.45 (2026-05-18 close) · hit pre-market · 1 other ENTA headline(s) in the window, move may be shared
day 0 close · peak
+2.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • EPS-3903 shows preferential distribution in lung and alveolar macrophages.
  • Low potential for drug-drug interactions enhances its therapeutic profile.
  • Promising candidate for asthma treatment.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~63 mo
Minimal dilution risk
Lead asset
EDP-235
Phase 2 · COVID-19

Full Press Release Details

• About About Us Management Team Board of Directors Timeline
• Pipeline Overview Hepatitis C Virus Respiratory Syncytial Virus SARS-CoV-2 Immunology KIT Inhibition STAT6 Inhibition MRGPRX2
• Science Overview Publications
• Patients Overview Clinical Trials Expanded Access Policy Resources
• Careers Join Us Culture Core Values Testimonials Benefits
• Collaborations Partnering
• Investors Overview Press Releases Events & Presentations Stock Information Stock Quote & Chart Historic Price Lookup Investment Calculator Analyst Coverage Financials Quartlery Results Annual Reports SEC Filings Corporate Responsibility Overview Environmental Social Governance Investor Resources Investor FAQs RSS Feed 2026 Annual Meeting Email Alerts
• Contact Us
• About Us
• Management Team
• Board of Directors
• Timeline
• Overview
• Hepatitis C Virus
• Respiratory Syncytial Virus
• SARS-CoV-2
• Immunology KIT Inhibition STAT6 Inhibition MRGPRX2
• KIT Inhibition
• STAT6 Inhibition
• MRGPRX2
• Overview
• Publications
• Overview
• Clinical Trials
• Expanded Access Policy
• Resources
• Join Us
• Culture
• Core Values
• Testimonials
• Benefits
• Partnering
• Overview
• Press Releases
• Events & Presentations
• Stock Information Stock Quote & Chart Historic Price Lookup Investment Calculator Analyst Coverage
• Financials Quartlery Results Annual Reports SEC Filings
• Corporate Responsibility Overview Environmental Social Governance
• Investor Resources Investor FAQs RSS Feed
• 2026 Annual Meeting
• Email Alerts
• Stock Quote & Chart
• Historic Price Lookup
• Investment Calculator
• Analyst Coverage
• Quartlery Results
• Annual Reports
• SEC Filings
• Overview
• Environmental
• Social
• Governance
• Investor FAQs
• RSS Feed
• Print Page Print Page
• Email Alerts Email Alerts
• RSS Feeds RSS Feeds
• Contact IR Contact IR

Frequently Asked Questions

What is EPS-3903?

EPS-3903 is a potent oral STAT6 inhibitor designed for asthma treatment.

How does EPS-3903 work?

It inhibits STAT6, which plays a role in inflammatory responses in asthma.

What are the benefits of EPS-3903?

It shows preferential distribution in lung macrophages and low drug interaction potential.

Is EPS-3903 safe for asthma patients?

Its low potential for drug-drug interactions suggests a favorable safety profile.

ShareAdd on Google
Tags: ENTA Viatris Investor Conferences Healthcare EPS-3903 asthma treatment STAT6 inhibition drug-drug interaction lung distribution
Last updated: May 19, 2026

Biotech snapshot

Cash runway
$211M liquidity · $3M/mo burn
~63 mo
Minimal dilution risk
Lead asset
EDP-235Phase 2
COVID-19 →